行情

FENC

FENC

Fennec Pharms
NASDAQ

实时行情|Nasdaq Last Sale

6.34
+0.07
+1.05%
休市 16:00 12/06 EST
开盘
6.39
昨收
6.27
最高
6.40
最低
6.22
成交量
3.33万
成交额
--
52周最高
7.65
52周最低
3.255
市值
1.17亿
市盈率(TTM)
-10.3730
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FENC 新闻

  • 意大利再次修正2020财政预算案 推多项惠民政策
  • 中国新闻网.5天前
  • 兴业银行:美国国债收益率或将因衰退风险而跌至1.2%
  • 新浪财经综合.5天前
  • 波音737 MAX审查进展:FAA局长将赴众院说明情况
  • 中国新闻网.5天前
  • 美股超级牛派:最近的下跌是早来的圣诞礼物
  • 新浪财经.5天前

更多

所属板块

生物技术和医学研究
+0.66%
制药与医学研究
+0.49%

热门股票

名称
价格
涨跌幅

FENC 简况

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
展开

Webull提供Fennec Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。